Insights
Search Results
Client Highlights
6.01.26
Firm Advises Edgewise Therapeutics on Its Sale of Sevasemten for up to $2.65 Billion
On June 1, 2026, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten, an orally administered fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies, and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The transaction strengthens Edgewise’s balance sheet, providing enhanced financial flexibility and sharpening the company’s strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline. Wilson Sonsini Goodrich & Rosati advised Edgewise on the transaction.
Client Highlights
1.27.26
Wilson Sonsini Advises Genyro on License Agreement with Caltech for “Sidewinder” Technology
On January 26, 2026, Genyro Inc., an early-stage, California-based biotechnology company advancing next-generation DNA construction, announced that it has entered into an exclusive licensing agreement with the California Institute of Technology (Caltech) for Sidewinder™, a breakthrough DNA construction invention recently featured in Nature. Wilson Sonsini Goodrich & Rosati advises Genyro on IP and corporate matters and represented the company in the licensing agreement with Caltech.
Sidewinder represents the first DNA construction technology based on DNA 3-Way Junctions (3WJ), enabling the accurate construction of long, complex, and highly repetitive DNA sequences that have historically been challenging to build. The technology was developed by Professor Kaihang Wang, tenure-track assistant professor of biology and biological engineering at Caltech and co-founder and chief scientific advisor at Genyro. It is the first DNA construction method to separate the sequence information of the final assembled DNA product from the information guiding its assembly.
The Wilson Sonsini team advising Genyro includes Karen Deschaine, Lou Lieto, and Nellie Brutocao.
For more information, please see Genyro’s news release. Additional coverage of Genyro is available in The Times and Endpoints News.
Sidewinder represents the first DNA construction technology based on DNA 3-Way Junctions (3WJ), enabling the accurate construction of long, complex, and highly repetitive DNA sequences that have historically been challenging to build. The technology was developed by Professor Kaihang Wang, tenure-track assistant professor of biology and biological engineering at Caltech and co-founder and chief scientific advisor at Genyro. It is the first DNA construction method to separate the sequence information of the final assembled DNA product from the information guiding its assembly.
The Wilson Sonsini team advising Genyro includes Karen Deschaine, Lou Lieto, and Nellie Brutocao.
For more information, please see Genyro’s news release. Additional coverage of Genyro is available in The Times and Endpoints News.
News Articles
7.11.25
Lawdragon Names 12 Wilson Sonsini Lawyers to Its 2025 List of Next-Generation Lawyers
Twelve Wilson Sonsini attorneys have been recognized in the 2025 Lawdragon 500 X – The Next Generation, the third edition of the guide. Individuals listed in the guide traditionally have “proven themselves early in private practice, accruing credentials, deals, and cases early and often,” with the majority of lawyers having been in practice between seven and fifteen years.
Client Highlights
3.17.25
Firm Advises Taiho Pharmaceutical on Acquisition of Araris Biotech for Up to $1.1 Billion
On March 17, 2025, Taiho Pharmaceutical Co., Ltd., an R&D-driven specialty pharmaceutical company focusing on the fields of oncology and immune-related diseases, and Araris Biotech AG, a Swiss biotechnology company developing next-generation antibody drug conjugates (ADCs), announced that they have entered into a definitive agreement pursuant to which Taiho Pharmaceutical will acquire Araris. Under the terms of the agreement, Taiho Pharmaceutical will pay $400 million at closing, with the potential for additional milestone payments of up to $740 million. The acquisition, which is expected to be completed in the first half of 2025, follows a research collaboration between Taiho Pharmaceutical and Araris signed in November 2023. Wilson Sonsini Goodrich & Rosati advised Taiho Pharmaceutical on the acquisition.
Araris is a spin-off company of the Paul-Scherrer-Institute in Switzerland and is pioneering the development of best-in-class ADCs with superior design, high linker solubility, and simple manufacturing that address the shortcomings of current generation ADCs. Taiho Pharmaceutical, in addition to antimetabolites, has established and created novel drugs through its proprietary small molecule drug discovery platform, Cysteinomix, enhancing cancer treatment and contributing to patient care. By acquiring Araris' innovative ADC drug discovery technology platform, Taiho Pharmaceutical will further expand its ongoing development portfolio in the field of oncology.
The Wilson Sonsini team that advised Taiho Pharmaceutical on the transaction included Miranda Biven, Jason Breen, Nellie Brutocao, and Ken Clark.
For more information, please see the companies’ joint news release. Additional coverage is available on Fierce Biotech and BioSpace.
Araris is a spin-off company of the Paul-Scherrer-Institute in Switzerland and is pioneering the development of best-in-class ADCs with superior design, high linker solubility, and simple manufacturing that address the shortcomings of current generation ADCs. Taiho Pharmaceutical, in addition to antimetabolites, has established and created novel drugs through its proprietary small molecule drug discovery platform, Cysteinomix, enhancing cancer treatment and contributing to patient care. By acquiring Araris' innovative ADC drug discovery technology platform, Taiho Pharmaceutical will further expand its ongoing development portfolio in the field of oncology.
The Wilson Sonsini team that advised Taiho Pharmaceutical on the transaction included Miranda Biven, Jason Breen, Nellie Brutocao, and Ken Clark.
For more information, please see the companies’ joint news release. Additional coverage is available on Fierce Biotech and BioSpace.
Client Highlights
2.18.25
Wilson Sonsini Advises Esperto Medical on Oversubscribed Series A
On February 18, 2025, Esperto Medical™, a healthtech start-up specializing in critical care and remote patient monitoring, announced the closing of an oversubscribed Series A investment round co-led by Catalyst Health Ventures and Bold Capital Partners, with support from Wavemaker Three-sixty Health, Free Flow Ventures, Fund@Caltech, and Maverick Ventures. Wilson Sonsini Goodrich & Rosati advised Esperto on the transaction.
Press Releases
11.15.24
Wilson Sonsini Goodrich & Rosati Elects 16 New Partners
Contact:
Kimberly Brooks
Wilson Sonsini
+1 212.453.2881
kbrooks@wsgr.com
Kimberly Brooks
Wilson Sonsini
+1 212.453.2881
kbrooks@wsgr.com
Client Highlights
10.18.24
Wilson Sonsini Advises Terray Therapeutics on $120M Series B Funding
On October 17, 2024, Terray Therapeutics, a Los Angeles-based biotechnology company improving human health by enhancing small molecule drug development, announced that it raised $120 million in Series B funding. The round was led by Bedford Ridge Capital and existing investor NVentures (NVIDIA’s venture capital arm), with participation from new and existing investors, including Maverick Capital, Goldcrest Capital, Madrona Ventures, Two Sigma Ventures, XTX Ventures, Digitalis Ventures, and Alexandria Ventures. Wilson Sonsini Goodrich & Rosati advised Terray on the transaction.
Client Highlights
8.09.24
Wilson Sonsini Advises Recursion on Definitive Agreement with Exscientia
On August 8, 2024, Recursion and Exscientia announced the companies have entered into a definitive agreement, combining Recursion, a leading clinical stage technology-enabled biotech company decoding biology to industrialize drug discovery, with Exscientia, a technology-driven clinical stage drug design and development company, committed to creating more effective medicines for patients, faster. Wilson Sonsini Goodrich & Rosati advised Recursion on the transaction.
Client Highlights
6.12.24
Wilson Sonsini Advises Ochre Bio on $37.5 Million License Agreement with GSK to Investigate Liver Disease
On June 12, 2024, Ochre Bio, a pioneer in chronic liver disease medicine development, announced the start of a multi-year data license agreement with GSK. The partnership will provide GSK with access to Ochre Bio’s computational biology, cellular, and perfused human organ platforms to generate proprietary human liver datasets and non-exclusive access to their extensive library of historical liver data. This license agreement includes data to be generated from single-cell sequencing to study cell populations in perfused human livers, as well as data generated from large-scale gene perturbation in human liver cells. The deal has a total value of up to $37.5 million for both co-exclusive and non-exclusive data licenses.
Client Highlights
8.12.22
Wilson Sonsini Advises BigHat Biosciences on IP and Licensing Matters Related to $75 Million Series B
On July 20, 2022, BigHat Biosciences, a biotechnology company developing safer, more effective antibody therapies for patients using machine learning and synthetic biology, announced the completion of a Series B financing of $75 million led by Section 32, with participation from new investors Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, and GRIDS Capital. Prior investors Andreessen Horowitz, 8VC, and AME Cloud Ventures also contributed to this round. The company has raised over $100 million to date. Wilson Sonsini Goodrich & Rosati provides support in IP and licensing matters to BigHat Biosciences.
Client Highlights
12.08.21
Wilson Sonsini Advises Recursion on Machine Learning-Based Drug Discovery Collaboration with Roche, Genentech
On December 7, 2021, Recursion, a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development, and beyond, announced a transformational collaboration with Roche and Genentech, a member of the Roche Group. Recursion will work with both Roche and Genentech's R&D units to leverage technology-enabled drug discovery through the Recursion Operating System (OS) to more rapidly identify novel targets and advance medicines in key areas of neuroscience as well in an oncology indication. Under the terms of the agreement, Recursion will receive an upfront payment of $150 million and is eligible for additional performance-based research milestones. Under the collaboration, Roche and Genentech (combined) may initiate up to 40 programs, each of which, if successfully developed and commercialized, could yield more than $300 million in development, commercialization, and net sales milestones for Recursion, as well as tiered royalties on net sales.
Client Advisories
11.15.21
Wilson Sonsini Advises Combangio in Its Acquisition by Kala Pharmaceuticals
On November 15, 2021, Kala Pharmaceuticals, a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye, announced that it has acquired Combangio, a private, clinical-stage company developing regenerative biotherapies for severe ocular surface diseases. Combangio is developing CMB-012, a novel investigational secretome therapy, now known as KPI-012, to address the complex wound healing process in persistent corneal epithelial defect (PCED) and other severe ocular diseases driven by impaired corneal healing. Wilson Sonsini Goodrich & Rosati represented Combangio in the transaction.